Clinical Trial Update: Safety/Efficacy Study of Optimizing Ibuprofen Dosing to Achieve Higher PDA Closure Rates [Phase 4]

View source ↗

Summary

A Phase 4 safety/efficacy trial evaluating optimized ibuprofen dosing for higher patent ductus arteriosus closure rates was TERMINATED.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Patent Ductus Arteriosus

Drugs mentioned

• ADVIL (IBUPROFEN)
• Ibuprofen (IBUPROFEN)
• Motrin (ibuprofen)

Snippet

Sponsor: OSF Healthcare System | Conditions: Patent Ductus Arteriosus | Phase 4 | Status: TERMINATED